Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
G Morad, BA Helmink, P Sharma, JA Wargo - Cell, 2021 - cell.com
Unprecedented advances have been made in cancer treatment with the use of immune
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …
Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors
A Chennamadhavuni, L Abushahin, N Jin… - Frontiers in …, 2022 - frontiersin.org
Immune-related adverse events (irAEs) are a range of complications associated with the use
of immune-checkpoint inhibitors (ICIs). Two major classes of ICIs widely used are Cytotoxic …
of immune-checkpoint inhibitors (ICIs). Two major classes of ICIs widely used are Cytotoxic …
T cells specific for α-myosin drive immunotherapy-related myocarditis
ML Axelrod, WC Meijers, EM Screever, J Qin… - Nature, 2022 - nature.com
Immune-related adverse events, particularly severe toxicities such as myocarditis, are major
challenges to the utility of immune checkpoint inhibitors (ICIs) in anticancer therapy. The …
challenges to the utility of immune checkpoint inhibitors (ICIs) in anticancer therapy. The …
Immune-related adverse events and the balancing act of immunotherapy
The benefit from immune checkpoint inhibitors is tempered by immunologic toxicities, which
involve diverse organs, have varying biology, onset time, and severity. Herein, we identify …
involve diverse organs, have varying biology, onset time, and severity. Herein, we identify …
Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non–small cell lung cancer
Importance The spectrum of individual immune-related adverse events (irAEs) from anti–
programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) immune …
programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) immune …
Tumor mutational burden quantification from targeted gene panels: major advancements and challenges
L Fancello, S Gandini, PG Pelicci… - Journal for immunotherapy …, 2019 - Springer
Tumor mutational burden (TMB), the total number of somatic coding mutations in a tumor, is
emerging as a promising biomarker for immunotherapy response in cancer patients. TMB …
emerging as a promising biomarker for immunotherapy response in cancer patients. TMB …
Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases
Immune-checkpoint inhibitors (ICIs) have dramatically changed the management of
advanced cancers. Designed to enhance the antitumour immune response, they can also …
advanced cancers. Designed to enhance the antitumour immune response, they can also …
Harnessing big data to characterize immune-related adverse events
Immune-checkpoint inhibitors (ICIs) have transformed patient care in oncology but are
associated with a unique spectrum of organ-specific inflammatory toxicities known as …
associated with a unique spectrum of organ-specific inflammatory toxicities known as …
[HTML][HTML] Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors
E De Martin, JM Michot, O Rosmorduc, C Guettier… - JHEP Reports, 2020 - Elsevier
Immune checkpoint inhibitors (ICIs) improve clinical outcomes in patients suffering from
different types of cancer. Liver toxicity is one of the immune-related adverse events …
different types of cancer. Liver toxicity is one of the immune-related adverse events …
Intratumoral immunotherapy: from trial design to clinical practice
S Champiat, L Tselikas, S Farhane, T Raoult… - Clinical Cancer …, 2021 - AACR
Systemic immunotherapies such as immune checkpoint blockade targeted at PD (L) 1 and
CTLA4 have demonstrated their ability to provide durable tumor responses and long-term …
CTLA4 have demonstrated their ability to provide durable tumor responses and long-term …